Biosimilars On Track - Base Business Margin Growth: yyProgress in R&D: Biocon's biosimilars and novel molecules program is on track as was expected. The company is analyzing the study results of IN-105 and renamed it as Insulin Tregopil as INN granted by WHO. The company has taken an mpairment loss on account of US rights of Itolizumab as US access which might not be expeditious. The other phase-III studies are progressing with Glargine patient recruitment completed and nearing completion in Pegfilgrastim and Trastuzumab. The R&D expenditure increased by 62% YoY in Q2FY16.